Trial Profile
Fibrinogen concentrate supplementation in the management of bleeding during paediatric cardiopulmonary bypass: a phase 1B/2A, open label dose escalation study
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Nov 2022
Price :
$35
*
At a glance
- Drugs Fibrinogen (Primary)
- Indications Surgical blood loss
- Focus Pharmacokinetics
- Acronyms FIBCON
- 09 Nov 2022 Results of a mechanistic sub-study assessing factor XIII levels, clot strength, and impact of fibrinogen concentrate in infants undergoing cardiopulmonary bypass published in the British Journal of Anaesthesia
- 03 Mar 2016 Accrual to date is 94% according to United Kingdom Clinical Research Network record.
- 02 Mar 2016 Status changed from recruiting to completed as per ISRCTN: Current Controlled Trials record.